Intervacc (Q2 initial take): Few surprises – all eyes on the label extension - Redeye

Q2 contained few surprises, and the small absolute figures remain of limited importance to our estimates. Instead, we focus on the recently submitted label extension, which we regard as a key catalyst for Strangvac’s commercial adoption.

Länk till analysen i sin helhet: https://www.redeye.se/research/1180413/intervacc-q2-initial-take-few-surprises-all-eyes-on-the-label-extension?utm_source=finwire&utm_medium=RSS